INS018_055

DRUG3 trials

Sponsors

InSilico Medicine Hong Kong Limited

Conditions

Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)

Phase 1

A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects

CompletedNCT05154240

InSilico Medicine Hong Kong LimitedIdiopathic Pulmonary Fibrosis

Start: 2022-02-21End: 2022-12-02Updated: 2023-06-29

Phase 2

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)

CompletedNCT05938920

InSilico Medicine Hong Kong LimitedIdiopathic Pulmonary Fibrosis (IPF)

Start: 2023-06-19End: 2024-08-08Updated: 2025-12-11

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

RecruitingNCT05975983

InSilico Medicine Hong Kong LimitedIdiopathic Pulmonary Fibrosis (IPF)

Start: 2024-02-08End: 2026-02-28Target: 40Updated: 2025-11-12

Related Papers

A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial

Nature Medicine2025-06-0347 citations

INS018-055, A Novel Traf2- and NCK-interacting Kinase (TNIK) Inhibitor, Improves Lung Function in Patients With Idiopathic Pulmonary Fibrosis: Results From a Randomized, Double-blind, Placebo-controlled Phase 2a Study

American Journal of Respiratory and Critical Care Medicine2025-05-012 citations

A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models.

2024-03-08138 citations